MYB Antikörper (AA 119-135)
Kurzübersicht für MYB Antikörper (AA 119-135) (ABIN3026200)
Target
Alle MYB Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
Klon
-
-
Bindungsspezifität
- AA 119-135
-
Verwendungszweck
- c-Myb Antibody (azide and preservative free)
-
Sequenz
- RRKVEQEGYP QESSKAG
-
Aufreinigung
- Protein G affinity chromatography
-
Immunogen
- Amino acids 119-135 (RRKVEQEGYPQESSKAG) from the human protein were used as the immunogen for this c-Myb antibody.
-
Isotyp
- IgG1, kappa
-
-
-
-
Applikationshinweise
- The optimal dilution of the c-Myb antibody for each application should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Konservierungsmittel
- Azide free
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store the c-Myb antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- MYB (V-Myb Myeloblastosis Viral Oncogene Homolog (Avian) (MYB))
-
Andere Bezeichnung
- c-Myb
-
Hintergrund
- The highly leukemogenic avian retrovirus E26 contains two oncogenes, v-Myb and v-Ets, which are expressed together as a fusion protein. The cellular homolog of v-Myb, designated c-Myb, encodes a transcription factor. Deletion or disruption of a negative regulatory domain mapping within the carboxy-terminal domain of c-Myb results in enhanced transactivating capacity and in parallel, leads to activation of its ability to transform hemopoietic cells. c-Myb is expressed preferentially, but not exclusively, in immature hemopoietic cells and its expression decreases as cells differentiate.
-
UniProt
- P01104
-
Pathways
- Chromatin Binding, Positive Regulation of Immune Effector Process
Target
-